Lanolin

drug
On this page

Also known as Adeps lanaeAnhydrous lanolinEmery 1600EuceriteLanolin - anhydrousLanolin anhydrousanhydrousanhydrous liquidOvis ariesPurified lanolinSuintineWool fatWool greaseWool wax

Summary

Lanolin (CHEMBL2108387) is a phase-3 clinical-stage unknown.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Clinical trials: 3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108387
NameLanolin
TypeUnknown
Max phase3

Also known as: Adeps lanae, Anhydrous lanolin, Emery 1600, Eucerite, Lanolin, Lanolin - anhydrous, Lanolin anhydrous, anhydrous, anhydrous liquid, Ovis aries, Purified lanolin, Suintine

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

PhaseTrials
PHASE42
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01420419PHASE4COMPLETEDEvaluating Lanolin for the Treatment of Nipple Pain Among Breastfeeding Women
NCT03389516PHASE4UNKNOWNHealing Nipple Wounds: Comparison Between 2 Treatment Modalities
NCT04153513PHASE2COMPLETEDEffect of Lanolin and Breastmilk in the Treatment of Sore and Damaged Nipples in Breastfeeding Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.